Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

The Spi1/PU.1 transcription factor accelerates replication fork progression by increasing PP1 phosphatase in leukemia.

Rimmelé P, Esposito M, Delestré L, Guervilly JH, Ridinger-Saison M, Despras E, Moreau-Gachelin F, Rosselli F, Guillouf C.

Oncotarget. 2017 Jun 6;8(23):37104-37114. doi: 10.18632/oncotarget.16183.

2.

Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia.

Ridinger-Saison M, Evanno E, Gallais I, Rimmelé P, Selimoglu-Buet D, Sapharikas E, Moreau-Gachelin F, Guillouf C.

Cell Death Differ. 2013 Sep;20(9):1268-78. doi: 10.1038/cdd.2013.88. Epub 2013 Jul 12.

3.

Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.

Selimoglu-Buet D, Gallais I, Denis N, Guillouf C, Moreau-Gachelin F.

PLoS One. 2012;7(11):e49052. doi: 10.1371/journal.pone.0049052. Epub 2012 Nov 7.

4.

Spi-1/PU.1 activates transcription through clustered DNA occupancy in erythroleukemia.

Ridinger-Saison M, Boeva V, Rimmelé P, Kulakovskiy I, Gallais I, Levavasseur B, Paccard C, Legoix-Né P, Morlé F, Nicolas A, Hupé P, Barillot E, Moreau-Gachelin F, Guillouf C.

Nucleic Acids Res. 2012 Oct;40(18):8927-41. doi: 10.1093/nar/gks659. Epub 2012 Jul 11.

5.

Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.

Buet D, Gallais I, Lauret E, Denis N, Lombard B, Guillonneau F, Kosmider O, Loew D, Dusanter-Fourt I, Guillouf C, Mayeux P, Moreau-Gachelin F.

Blood. 2012 May 3;119(18):4228-41. doi: 10.1182/blood-2011-07-368316. Epub 2012 Mar 20.

PMID:
22438255
6.

Spi-1/PU.1 oncogene accelerates DNA replication fork elongation and promotes genetic instability in the absence of DNA breakage.

Rimmelé P, Komatsu J, Hupé P, Roulin C, Barillot E, Dutreix M, Conseiller E, Bensimon A, Moreau-Gachelin F, Guillouf C.

Cancer Res. 2010 Sep 1;70(17):6757-66. doi: 10.1158/0008-5472.CAN-09-4691. Epub 2010 Jul 21.

7.

Erythropoietin down-regulates stem cell factor receptor (Kit) expression in the leukemic proerythroblast: role of Lyn kinase.

Kosmider O, Buet D, Gallais I, Denis N, Moreau-Gachelin F.

PLoS One. 2009 May 28;4(5):e5721. doi: 10.1371/journal.pone.0005721.

8.

Spi-1 and Fli-1 directly activate common target genes involved in ribosome biogenesis in Friend erythroleukemic cells.

Juban G, Giraud G, Guyot B, Belin S, Diaz JJ, Starck J, Guillouf C, Moreau-Gachelin F, Morlé F.

Mol Cell Biol. 2009 May;29(10):2852-64. doi: 10.1128/MCB.01435-08. Epub 2009 Mar 16.

9.

Multi-stage Friend murine erythroleukemia: molecular insights into oncogenic cooperation.

Moreau-Gachelin F.

Retrovirology. 2008 Nov 4;5:99. doi: 10.1186/1742-4690-5-99. Review.

10.

Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia.

Monni R, Haddaoui L, Naba A, Gallais I, Arpin M, Mayeux P, Moreau-Gachelin F.

Blood. 2008 Mar 15;111(6):3163-72. doi: 10.1182/blood-2007-09-110510. Epub 2008 Jan 8.

PMID:
18182570
11.

Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.

Kosmider O, Denis N, Dubreuil P, Moreau-Gachelin F.

Oncogene. 2007 May 31;26(26):3904-8. Epub 2006 Dec 18.

PMID:
17173066
12.
13.

Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation.

Rimmelé P, Kosmider O, Mayeux P, Moreau-Gachelin F, Guillouf C.

Blood. 2007 Apr 1;109(7):3007-14.

PMID:
17132716
14.

Spi-1/PU.1 oncoprotein affects splicing decisions in a promoter binding-dependent manner.

Guillouf C, Gallais I, Moreau-Gachelin F.

J Biol Chem. 2006 Jul 14;281(28):19145-55. Epub 2006 May 11.

15.

From mice to human: the "two-hit model" of leukemogenesis.

Kosmider O, Moreau-Gachelin F.

Cell Cycle. 2006 Mar;5(6):569-70. Epub 2006 Mar 15. Review. No abstract available.

PMID:
16582609
16.

Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.

Kosmider O, Denis N, Lacout C, Vainchenker W, Dubreuil P, Moreau-Gachelin F.

Cancer Cell. 2005 Dec;8(6):467-78.

17.

PU.1/Spi-1 binds to the human TAL-1 silencer to mediate its activity.

Le Clech M, Chalhoub E, Dohet C, Roure V, Fichelson S, Moreau-Gachelin F, Mathieu D.

J Mol Biol. 2006 Jan 6;355(1):9-19. Epub 2005 Nov 8.

PMID:
16298389
18.

Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.

Barnache S, Le Scolan E, Kosmider O, Denis N, Moreau-Gachelin F.

Oncogene. 2006 Mar 2;25(9):1420-3.

PMID:
16247441
19.

Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression.

Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, Levade T, Moreau-Gachelin F.

Blood. 2005 Sep 1;106(5):1808-16. Epub 2005 May 12.

PMID:
15890687
20.
21.

Potential autoregulation of transcription factor PU.1 by an upstream regulatory element.

Okuno Y, Huang G, Rosenbauer F, Evans EK, Radomska HS, Iwasaki H, Akashi K, Moreau-Gachelin F, Li Y, Zhang P, Göttgens B, Tenen DG.

Mol Cell Biol. 2005 Apr;25(7):2832-45.

22.

Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells.

Delva L, Gallais I, Guillouf C, Denis N, Orvain C, Moreau-Gachelin F.

Oncogene. 2004 May 27;23(25):4389-99.

PMID:
15064749
23.

Spi-1/PU.1 but not Fli-1 inhibits erythroid-specific alternative splicing of 4.1R pre-mRNA in murine erythroleukemia cells.

Théoleyre O, Deguillien M, Morinière M, Starck J, Moreau-Gachelin F, Morlé F, Baklouti F.

Oncogene. 2004 Jan 29;23(4):920-7.

PMID:
14647452
24.

Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors.

Giraudier S, Chagraoui H, Komura E, Barnache S, Blanchet B, LeCouedic JP, Smith DF, Larbret F, Taksin AL, Moreau-Gachelin F, Casadevall N, Tulliez M, Hulin A, Debili N, Vainchenker W.

Blood. 2002 Oct 15;100(8):2932-40.

PMID:
12351405
26.

Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts.

Scolan EL, Wendling F, Barnache S, Denis N, Tulliez M, Vainchenker W, Moreau-Gachelin F.

Oncogene. 2001 Sep 6;20(39):5484-92.

27.

Identification of an RNA binding specificity for the potential splicing factor TLS.

Lerga A, Hallier M, Delva L, Orvain C, Gallais I, Marie J, Moreau-Gachelin F.

J Biol Chem. 2001 Mar 2;276(9):6807-16. Epub 2000 Nov 29.

28.

Phosphorylation of the Spi-B transcription factor reduces its intrinsic stability.

Ray-Gallet D, Moreau-Gachelin F.

FEBS Lett. 1999 Dec 31;464(3):164-8.

29.

Spi-1/PU.1 proto-oncogene induces opposite effects on monocytic and erythroid differentiation of K562 cells.

Delgado MD, Gutiérrez P, Richard C, Cuadrado MA, Moreau-Gachelin F, León J.

Biochem Biophys Res Commun. 1998 Nov 18;252(2):383-91.

PMID:
9826539
30.

DMSO reduces CSF-1 receptor levels and causes apoptosis in v-myc immortalized mouse macrophages.

Marthyn P, Beuscart A, Coll J, Moreau-Gachelin F, Righi M.

Exp Cell Res. 1998 Aug 25;243(1):94-100.

PMID:
9716453
31.

Spi-1 transgenic mice develop a clonal erythroleukemia which does not depend on p53 mutation.

Barnache S, Wendling F, Lacombe C, Denis N, Titeux M, Vainchenker W, Moreau-Gachelin F.

Oncogene. 1998 Jun 11;16(23):2989-95.

32.

Isolation and characterization of a chicken homologue of the Spi-1/PU.1 transcription factor.

Kherrouche Z, Beuscart A, Huguet C, Flourens A, Moreau-Gachelin F, Stehelin D, Coll J.

Oncogene. 1998 Mar 12;16(10):1357-67.

33.

The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS.

Hallier M, Lerga A, Barnache S, Tavitian A, Moreau-Gachelin F.

J Biol Chem. 1998 Feb 27;273(9):4838-42.

34.

Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells.

Gutiérrez P, Delgado MD, Richard C, Moreau-Gachelin F, León J.

Biochem Biophys Res Commun. 1997 Nov 26;240(3):862-8.

PMID:
9398659
35.

An alternatively spliced isoform of the Spi-B transcription factor.

Ray-Gallet D, Tavitian A, Moreau-Gachelin F.

Biochem Biophys Res Commun. 1996 Jun 14;223(2):257-63.

PMID:
8670269
36.

The transcription factor Spi-1/PU.1 binds RNA and interferes with the RNA-binding protein p54nrb.

Hallier M, Tavitian A, Moreau-Gachelin F.

J Biol Chem. 1996 May 10;271(19):11177-81.

37.

Spi-1/PU.1 transgenic mice develop multistep erythroleukemias.

Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, Grimber G, Briand P, Vainchenker W, Tavitian A.

Mol Cell Biol. 1996 May;16(5):2453-63.

38.

Differential phosphorylations of Spi-B and Spi-1 transcription factors.

Mao C, Ray-Gallet D, Tavitian A, Moreau-Gachelin F.

Oncogene. 1996 Feb 15;12(4):863-73.

PMID:
8632909
39.

PU.1 (Spi-1) autoregulates its expression in myeloid cells.

Chen H, Ray-Gallet D, Zhang P, Hetherington CJ, Gonzalez DA, Zhang DE, Moreau-Gachelin F, Tenen DG.

Oncogene. 1995 Oct 19;11(8):1549-60.

PMID:
7478579
40.
41.

Spi-1/PU.1: an oncogene of the Ets family.

Moreau-Gachelin F.

Biochim Biophys Acta. 1994 Dec 30;1198(2-3):149-63. Review. No abstract available.

PMID:
7819272
43.
44.

Inhibition of Friend cells proliferation by spi-1 antisense oligodeoxynucleotides.

Delgado MD, Hallier M, Meneceur P, Tavitian A, Moreau-Gachelin F.

Oncogene. 1994 Jun;9(6):1723-7.

PMID:
8183568
45.

Putative oncogenic role of the erythropoietin receptor in murine and human erythroleukemia cells.

Chretien S, Moreau-Gachelin F, Apiou F, Courtois G, Mayeux P, Dutrillaux B, Cartron JP, Gisselbrecht S, Lacombe C.

Blood. 1994 Apr 1;83(7):1813-21.

PMID:
8142650
46.

Functional interference between the Spi-1/PU.1 oncoprotein and steroid hormone or vitamin receptors.

Gauthier JM, Bourachot B, Doucas V, Yaniv M, Moreau-Gachelin F.

EMBO J. 1993 Dec 15;12(13):5089-96.

47.

Characterization of Spi-B, a transcription factor related to the putative oncoprotein Spi-1/PU.1.

Ray D, Bosselut R, Ghysdael J, Mattei MG, Tavitian A, Moreau-Gachelin F.

Mol Cell Biol. 1992 Oct;12(10):4297-304.

48.

Localization of the human oncogene SPI1 on chromosome 11, region p11.22.

Nguyen VC, Ray D, Gross MS, de Tand MF, Frézal J, Moreau-Gachelin F.

Hum Genet. 1990 May;84(6):542-6.

PMID:
2338340
49.

The human homologue of the putative proto-oncogene Spi-1: characterization and expression in tumors.

Ray D, Culine S, Tavitain A, Moreau-Gachelin F.

Oncogene. 1990 May;5(5):663-8. Erratum in: Oncogene 1990 Oct;5(10):1611-2.

PMID:
1693183
50.

Spi-1 oncogene activation in Rauscher and Friend murine virus-induced acute erythroleukemias.

Moreau-Gachelin F, Ray D, de Both NJ, van der Feltz MJ, Tambourin P, Tavitian A.

Leukemia. 1990 Jan;4(1):20-3.

PMID:
2153262

Supplemental Content

Loading ...
Support Center